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Abstract
Aim: The aim of this study was to evaluate oxidative stress from glutathione depletion in critically ill patients with a
septic shock through the abnormal presence of pyroglutamic acid (PyroGlu) in the urine (indirectly) and through its
serum level (directly).
Methods: This was a prospective analytical study of 28 critically ill patients with a septic shock who were
monitored from admission (initial) to 3 days of stay (final) in the intensive care unit (ICU). Data collected included
PyroGlu and glutamic acid (Glu) using liquid chromatography/mass spectrometry, and glutathione peroxidase (GPX)
activity with a colorimetric assay. The differences in Glu, PyroGlu, and GPX activity between the septic shock group
and healthy control group serving as reference values were evaluated using the Mann–Whitney test. The
correlations between Glu, PyroGlu, and GPX activity and clinical outcomes were determined using Spearman’s
correlation coefficient.
Results: In patients with septic shock, serum and urine PyroGlu levels were higher, erythrocyte GPX activity/gr Hb
was lower, and urine Glu levels were lower compared to healthy control reference values, for both initial and final
values. Initial serum Glu levels were also lower. Serum PyroGlu levels had a correlation with both initial and final
serum Glu levels; levels also correlated in the urine. Initial serum Glu correlated with the days of mechanical
ventilation (P = 0.016) and the days of ICU stay (P = 0.05). Urine Glu/mg creatinine correlated with APACHE II (P = 0.
030). This positive correlation observed for serum Glu was not observed for PyroGlu.
Conclusions: The current study found that septic patients have higher levels of PyroGlu, lower levels of Glu, and
lower erythrocyte GPX activity, suggesting that these biomarkers could be used as an indicator of glutathione
depletion. In addition, Glu is related to severity parameters. This study can guide future studies on the importance
of monitoring the levels of pyroglutamic acidosis in critical patients with septic shock in order to preserve the
oxidative status and its evolution during the stay in the ICU.
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Background
Septic shock is the leading cause of death in the inten-
sive care unit (ICU), and despite increased knowledge
about the pathogenesis of sepsis, its mortality rate re-
mains high, approximately 20 to 80% [1–3]. The excess
oxidative stress in sepsis is produced by both an excess
production of free radicals and a deficit in antioxidant
defenses (scavengers). One of the most important and
most abundant defensive antioxidant systems is the GPX
enzyme family (GPX). These enzymes require reduced
glutathione (GSH) for its action. One member of the
GPX enzyme family is cellular glutathione peroxidase
(GPX1), whose function is to detoxify peroxides in the
cell. GPX1 is found in the cytoplasm of cells, especially
red blood cells, and its main function is to protect
hemoglobin from the action of free radicals. Other en-
zymatic families with an important role in antioxidant
defense are the thioredoxin reductase.
Glutathione (GSH) is a non-protein tripeptide consist-
ing of three amino acids: glutamate, cysteine, and gly-
cine. More than 90% of total glutathione is in the
reduced form (GSH), and less than 10% is in the disul-
fide form (GSSG). An increase in the ratio between
GSSG and GSH is an indicator of oxidative stress.
Morris et al. described how GSH works to modulate the
behavior of many cells, conferring protection against mi-
crobial, viral, and parasitic infections [4]. It is well
known that the increase in oxidative stress causes the
decrease in GSH levels [5–8]. GSH biosynthesis by way
of the gamma-glutamyl cycle is important for maintain-
ing GSH homeostasis and normal redox status, this cycle
can be seen in Fig. 1. The function of this cycle, pro-
posed by Alton Meister [10], is the transfer of amino
acids, finally reaching GSH synthesis [11]. GSH is
decomposed into a gamma-glutamyl amino acid through
gamma-glutamyl transpeptidase. The gamma-glutamyl
amino acid is converted to pyroglutamic acid (PyroGlu)
through gamma-glutamyl cyclotransferase. PyroGlu is
converted to glutamic acid (Glu) through 5-oxoproli-
nase. Glu is converted to gamma-glutamylcysteine
through gamma-glutamylcysteine synthetase. Finally,
GSH is synthesized by glutathione synthetase.
The importance of the role of PyroGlu in critically ill
patients is not well documented. The acquired form of
pyroglutamic acid or 5-oxoproline (PyroGlu) metabolic
acidosis was first described in 1989. Since then, this
cause of chronic anion gap metabolic acidosis has been
increasingly recognized. Many cases go unrecognized
Fig. 1 Gamma-glutamyl cycle. Decreased levels of cellular glutathione lead to decreased feedback inhibition of γ-glutamylcysteinesynthetase, and
low glutathione levels would activate this enzyme. Under normal condition, high glutathione levels inhibit of γ-glutamylcysteine synthetase. This
results in excessive formation of the dipeptide γ-glutamylcysteine, which is converted by γ-glutamylcyclotransferase into pyroglutamic acid. The
overproduction of pyroglutamic acid exceeds the capacity of 5-oxoprolinase, and pyroglutamic acid therefore accumulates in body fluids and is
excreted in the urine [9]. This mechanism also explains the glutamic acid levels since the reaction catalyzed by 5-oxoprolinase is slower because it
depends on ATP
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because an assay for PyroGlu is limited in daily clinical
practice. Thus, the excess PyroGlu in a septic patient
without an enzymatic deficit in the gamma-glutamyl cycle
could be associated with GSH depletion, and therefore ex-
cessive oxidative stress and its negative consequences. A
decrease in GSH can be due to three reasons: (I) a de-
crease in ATP prevents the enzyme 5-oxoprolinasa (ATP--
dependent) from converting PyroGlu into Glu, causing
PyroGlu to accumulate, and thus, the gamma-glutamyl
cycle becomes blocked; (II) GSH depletion due to the
GSH demand caused by the need to eliminate free radicals
since the patient is in a state of increased oxidative stress;
(III) the activation of the enzyme gamma-glutamylcysteine
synthetase that helps the futile cycle to continue without
synthesizing GSH. In other words, the high presence of
PyroGlu contributes even further to GSH deficiency and
would be an indicator of high oxidative stress. The block-
ing of the cycle by low ATP is more likely associated with
a decrease of cysteine bioavailability. This cysteine bio-
availability decrease could be expected in a situation of
the increased requirement of cysteine for the protein syn-
thesis in immune cells. The blocking of the cycle is
expecting to increase the GSH depletion, but more as a
consequence than a cause. From these analyses, the con-
centrations of Glu and PyroGlu can be correlated with
clinical outcomes. Therefore, the aim of this study was to
assess pyroglutamic acidemia as an increased oxidative
stress predictor, since it contributes to GSH depletion in
critically ill patients with septic shock, its association with
morbidity and mortality, and its evolution after 3 days.
Materials and methods
Study design and patients
The design was a prospective analytical study monitoring
critically ill patients from admission until the third day of
their stay in the ICU of Virgen de las Nieves Hospital in
Granada (Spain). The study was approved by the hospital’s
Ethical Committee, and informed consent was obtained
from the patients or their family who had agreed to par-
ticipate in the study. A total of 28 consecutive patients
aged 18 years or older who were admitted to the ICU were
included in the study following consensus criteria of septic
shock [2]. The patients’ medical histories did not show
they were deficient in any enzyme of the gamma-glutamyl
cycle. Patients underwent parenteral or enteral nutrient
support but were not enriched with glutamine.
The following data was recorded on the day of inclu-
sion in the study (initial) and on the third day (final): pa-
tient age, diagnosis, sex, Acute Physiology and Chronic
Health Evaluation II (APACHE II) score, Sequential
Organ Failure Assessment (SOFA) score, ICU length of
stay, patient 28-day mortality, and cardiocirculatory
parameters.
Blood collection and handling
Initial and final blood and urine samples were collected.
Blood and urine samples were centrifuged immediately
at 3500 rpm for 10min at 4 °C and serum was collected.
Serum and urine samples were stored at − 80 °C prior to
biochemical analyses for subsequent testing. The refer-
ence values of PyroGlu, Glu, and GPX1 activity are un-
known. Twenty-eight serum and urine samples from
healthy patients were obtained to be used as reference
values, and these were also frozen at − 80 °C. The origin
of the control healthy people is from Granada region.
Biochemical parameters
The following initial and final data was recorded: blood
biochemical profile (acid-base balance: pH and anion
gap), renal function (creatinine, urea, and ions), liver
function (GOT, GPT, and bilirubin), nutrition parame-
ters (albumin, prealbumin, ferritin, transferrin, folic acid,
and vitamin B12 [vit B12]), and hematimetric and in-
flammatory parameters (C-reactive protein [CRP] and
procalcitonin [PCT]).
Assessment of pyroglutamic acid and glutamic acid
The urine and serum samples were thawed, and proteins
from the samples were precipitated with acetonitrile. 0.3
mL of the sample was placed in an Eppendorf tube, and
0.3 mL of 12.5% acetonitrile was added. Acetonitrile
preparation (1/8): 10 mL of acetonitrile was placed in a
test tube and completed with distilled water to 80mL.
The samples were shaken and then incubated at room
temperature, maintaining them with circular shaking
motion for 30 min. The samples were centrifuged at
14,000 rpm for 5 min, then 0.2 mL of the supernatant
was transferred to the screw cap bottle. Afterwards, the
samples were processed. PyroGlu and Glu levels were
obtained using liquid chromatography/mass spectrom-
etry (LC/MS).
Assessment of erythrocyte glutathione peroxidase activity
(GPX1 activity)
The GPX1 activity of red blood cell hemolysate was
assessed with a colorimetric assay using the Bioxytech®
kit (OxisResearch™). Aliquots of erythrocytes were mixed
into the four volumes of distilled water and centrifuged
at 10,000 rpm for 15 min at 4 °C, followed by the
addition of 3× Assay Buffer. Enzyme activity was evalu-
ated at 25 °C at a wavelength of 340 nm, and the results
were expressed in units per gram of hemoglobin.
Assessment of selenium
The determination of Se in patients’ plasma was carried
out in the Center of Scientific Instrumentation at the
University of Granada with the inductively coupled
plasma mass spectrometry (ICP-MS) method, using a
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Perkin-Elmer mass spectrometer with a plasma torch
ionization source and quadrupole Nex ION 300D ion
filter.
Statistical analysis
Statistical analysis was performed using SPSS version
21.0. Qualitative variables were presented as frequencies
and percentages, and quantitative variables as mean ±
standard deviation (SD). For continuous variables, the
assumption of normality was tested using the Shapiro–
Wilk test. The differences in Glu, PyroGlu, and GPX1
activity between the septic shock patient group and
healthy control group as reference values were evaluated
using the Mann–Whitney test. In order to analyze the
relationship between severity, ventilation, and clinical
parameters and both urine and serum Glu and PyroGlu
acid levels and erythrocyte GPX1 activity, the cutoff
scores were established by the median (low levels vs high
levels). The correlations between Glu, PyroGlu, and
GPX1 activity and clinical outcomes were determined
using Spearman’s correlation coefficient. Statistical sig-
nificance was defined as P < 0.05.
Results
Patient characteristics
During the study period, a total of 28 patients admitted
to the ICU were enrolled. Clinical characteristics are
shown in Table 1. The gender distribution of the sample
was 22 male patients (78.6%) and 6 female patients
(21.4%) with a mean age (SD) of 61.9 ± 14.1 years. The
original cause of septic shock was of abdominal (50%),
urinary (21%), and respiratory (29%) origin. The majority
of the cases had underlying diseases such as cardiocircu-
latory diseases, hyperlipidemia, diabetes, chronic ob-
structive pulmonary disease, and malignancy. Two cases
had HBV, another HIV disease and another only
hypothyroidism, which could interfere in the depletion
of antioxidants. The microorganisms that caused the in-
fection were one Acinetobacter, three Streptococci, one
Pseudomonas, one Candida albicans, one Campylobac-
ter, one Clostridium, and the rest were Escherichia coli.
The APACHE II score was 22.0 (17–27) at admission.
The SOFA score was 12.4 ± 2.60 and 8.88 ± 4.40 at ad-
mission and on the third day, respectively. The final
SOFA score decreased (P < 0.011). A total of 15 patients
needed mechanical ventilation (53.6%), and the mean
length of stay in the ICU was 7.04 ± 10.49 days. The ob-
served 28-day mortality was 42.9% (12 patients), 8 pa-
tients died in less than 72 h. Anion gap was associated
with initial APACHE II (P < 0.001).
Biochemical variables
Initial and final biochemical parameters and the evolution
after 3 days in patients with septic shock are shown in
Table 2. Patients met the clinical criteria for septic shock.
All the parameters were abnormal, with very high levels of
CRP and PCT (as acute markers of inflammation and in-
fection), while the markers for renal and hepatic insuffi-
ciency, as well as metabolic acidemia, were also very high.
Comparative analysis of serum and urine Glu and PyroGlu
levels and erythrocyte GPX1 activity
Table 3 shows the differences between patients with sep-
tic shock and reference values as controls for serum and
Table 1 Clinical characteristics initial and final, and the evolution after 3 days, of critically ill septic shock patients
Initial (mean ± SD) n = 28 Final (mean ± SD) n = 14 P value
Age, (years) 61.9 ± 14.1 – –
Male, number (%) 22 (78.6%) – –
Albumin (gr/dL) 2.72 ± 0.61 2.66 ± 0.65 0.139
Prealbumin (mg/dL) 12.67 ± 6.72 16.95 ± 10.67 0.143
Ferritin (ng/mL) 678.7 ± 946.6 529.3 ± 450.1 0.707
Transferrin (mg/dL) 139.3 ± 57.1 148.1 ± 51.3 0.514
SOFA score 12.4 ± 2.6 8.8 ± 4.4 0.011
APACHE II score 22.0 (17–27) – –
Sepsis focus, number (%)
Respiratory 14 (50%) – –
Urinary 6 (21%) – –
Abdominal 8 (29%) – –
SBP (mmHg) 67.1 ± 15.9 79.6 ± 10.9 0.009
FiO2 (%) 0.56 ± 0.17 0.40 ± 0.14 0.001
PaO2/FiO2 231.5 ± 81.6 240.1 ± 98.8 0.494
Values are expressed as mean ± standard deviation. The fourth column shows the statistical significance after applying the comparison of means for related
samples; thus, the evolution is shown after 3 days. SBP systolic blood pressure, PaO2/FiO2 partial oxygen arterial pressure/fraction of inspired oxygen
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urine PyroGlu, serum and urine Glu (urine results have
also been expressed divided by creatinine [/Crea]),
serum and erythrocyte Se, and GPX1 activity (which has
also been expressed divided by grams of Hb [/Hb]). The
control samples were taken from 28 healthy patients
with normal test results and similar ages. There were
statistically significant differences found between initial
and final values for urine PyroGlu/Crea levels (P =
0.002), urine Glu levels (P < 0.026), and GPX1/Hb activ-
ity (P = 0.008). In all three cases, the final levels in-
creased, except in the case of Glu/Crea which was not
significant. Serum and erythrocyte Se showed a statisti-
cally significant decrease (P = 0.001) between initial and
final values. However, no differences were found be-
tween initial and final serum Glu levels (P = 0.109) and
serum PyroGlu levels (P = 0.075).
Comparative analysis of severity, ventilation, and clinical
parameters for both urinary and serum Glu and PyroGlu
acid levels and erythrocyte GPX1 activity
Figure 2 shows the comparative analysis of severity and
clinical parameters for both urinary Glu and Pyro Glu
Table 2 Initial and final biochemical parameters, and the evolution after 3 days in patients with septic shock
Initial (mean ± SD) n = 28 Final (mean ± SD) n = 14 Reference values P value initial—final
pH 7.32 ± 0.09 7.38 ± 0.11 7.35–7.45 0.354
Anion gap (mmol/L) 12.1 ± 4.2 7.2 ± 10.7 7–16 0.079
Lactic acid (mmol/L) 4.72 ± 1.98 2.39 ± 2.17 0.6–2.5 0.008
Creatinine (mg/dL) 2.99 ± 1.47 2.35 ± 1.64 0.67–1.20 0.097
GOT or AST (U/L) 186.4 ± 299.6 964.1 ± 1947.5 5–40 0.255
GPT or ALT (U/L) 112.6 ± 128.3 506.4 ± 779.3 13–37 0.143
Total bilirubin (mg/dL) 2.37 ± 3.04 2.79 ± 3.07 0.3–1.2 0.431
CRP (mg/L) 35.1 ± 28.9 46.7 ± 53.5 0.02–5 0.679
Procalcitonin (ng/mL) 75.5 ± 59.3 42.6 ± 65.9 < 0.5 0.017
LDH (U/L) 620.0 ± 473.8 1285.9 ± 2130.7 110–295 0.211
Leukocytes (*103/μL) 15.3 ± 17.9 13.3 ± 68.4 3.5–10.5 0.816
Neutrophils (%) 84.7 ± 16.2 86.1 ± 6.0 42–77 0.241
Hemoglobin (g/dL) 11.2 ± 2.5 9.4 ± 2.1 11–17 0.001
Vitamin B12 (pg/mL) 976.4 ± 511.0 1118.7 ± 192.2 116–513 0.261
Values are expressed as mean ± standard deviation. The fifth column shows the statistical significance after applying the comparison of means for related samples;
thus, the evolution is shown after 3 days. GOT or AST glutamic oxaloacetic transaminase or aspartate transaminase, GPT or ALT glutamic pyruvic transaminase or
alanine transaminase, CRP C-reactive protein
Table 3 Serum and urine pyroglutamic acid, serum and urine glutamic acid, and erythrocyte glutathione peroxidase activity in
patients with septic shock compared with healthy control as reference values, and the evolution after 3 days, are shown in this table
Reference values (n = 28)
(mean ± SD)
Case initial (n = 28)
(mean ± SD)








Serum pyroglutamic acid (μg/L) 399.9 ± 77.1 696.7 ± 273.0 992.3 ± 442.6 0.001 0.001 0.075
Urine pyroglutamic acid (μg/L) 400.7 ± 234.5 522.9 ± 356.1 1790.3 ± 431.8 0.153 0.010 0.021
Urine pyroglutamic acid (μg/mg
creatinine)
0.40 ± 0.32 2.03 ± 2.29 3.92 ± 1.89 0.001 0.001 0.002
Serum glutamic acid (μg/L) 8.03 ± 2.73 5.74 ± 1.66 7.48 ± 2.26 0.001 0.497 0.190
Urine glutamic acid (μg/L) 30.3 ± 15.7 7.1 ± 4.7 13.2 ± 6.8 0.001 0.001 0.026
Urine glutamic acid (μg/mg
creatinine)
0.30 ± 0.18 0.24 ± 0.16 0.53 ± 0.45 0.196 0.103 0.092
Serum selenium (μg/L) 76.93 ± 18.14 56.03 ± 12.95 41.65 ± 11.46 0.001 0.001 0.001
Erythrocyte selenium (μg/L) 108.7 ± 23.3 79.6 ± 14.9 68.2 ± 15.1 0.001 0.001 0.001
Erythrocyte glutathione peroxidase
activity (mU/mL)
3980.5 ± 777.5 1265.3 ± 661.5 1412.7 ± 591.4 0.001 0.001 0.154
Erythrocyte glutathione peroxidase
activity (U/gr Hb)
26.5 ± 5.1 12.2 ± 6.6 16.2 ± 8.8 0.001 0.001 0.008
Values are expressed as mean ± standard deviation. P (5th and 6th columns) = statistical significance of healthy control as reference values vs cases. P (7th
column) = value case initial—case final, show the evolution after 3 days. Fifth and sixth columns show the statistical significance after applying the difference of
means for independent samples. The seventh column shows the statistical significance after applying the comparison of means for related samples
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levels, and initial erythrocyte GPX1 activity. Those pa-
tients with greater severity (APACHE II) showed higher
levels of Glu in urine (P < 0.05). On the other hand, pa-
tients with clinical parameters such as low PCT, low
LDH, and low lactic acid showed high levels of serum
PyroGlu and Glu and erythrocyte GPX1/Hb activity, re-
spectively (P < 0.05).
Analysis of serum and urine Glu and PyroGlu and
erythrocyte GPX1 activity correlation with inflammation
and severity status
PyroGlu, Glu, and GPX1 activity levels were associated
with severity parameters (APACHE II, SOFA, days of
mechanical ventilation, days of stay in ICU, and age)
and mortality. Positive correlations were observed be-
tween initial serum Glu and the days of mechanical
ventilation (r = 0.450, P = 0.016) and the duration of
ICU stay (r = 0.372, P < 0.05). This was also true for
initial urine Glu/Crea with APACHE II (r = 0.536, P =
0.030). This correlation was not observed in the case
of PyroGlu nor GPX1.
Figure 3 shows the Spearman’s correlation analysis be-
tween PyroGlu and Glu in serum and urine. Serum Pyr-
oGlu levels had a significant correlation with both initial
and final serum Glu levels (r = 0.651, P < 0.001) (Fig. 3a)
and (r = 0.767, P < 0.001), respectively. In the case of Pyr-
oGlu, a correlation between serum and urine/Crea was
also observed (r = 0.426, P < 0.034) as shown in Fig. 3b.
Moreover, a correlation was observed between urine
PyroGlu and Glu levels for both initial (r = 0.659, P <
0.001) (Fig. 3c) and final values (r = 0.665, P < 0.013), and
between initial urine PyroGlu/Crea and urine Glu/Crea
levels (r = 0.604, P = 0.002) (Fig. 3d).
Discussion
In the current study, we set out to evaluate pyroglutamic
acidemia in both serum and urine as an increased oxida-
tive stress predictor in critically ill patients with septic
shock as well as its association with clinical outcomes,
morbidity and mortality, and patient evolution in the ICU.
Our major finding showed high serum and urine PyroGlu
levels in critically ill patients. On the contrary, a decrease
in serum levels and urine Glu levels as well as GPX1 activ-
ity was observed in these patients compared to the refer-
ence values, although in the case of Glu, the urine
decrease was not observed if it is expressed in accordance
with mg of creatinine. This is the first time that PyroGlu
has been determined in septic shock patients and com-
pared with Glu, a metabolite of its cycle. As in this study,
a decrease in Glu was also observed in patients with septic
shock in other studies [12].
These disorders are attributed to glutathione depletion in
the gamma-glutamyl cycle [13], the mechanism for which is
shown in Fig. 1. The increase in PyroGlu could be due to
three key points: (I) the catabolism of GSH through
gamma-glutamyl transpeptidase, (II) and/or to a limiting
factor in the second step of gamma-glutamylcysteine synthe-
tase (III) or a limiting factor in the following step involving
glutathione synthetase. (II) The gamma-glutamylcysteine
synthetase enzyme is the main rate-limiting step in this
cycle, and this reaction is non-allosterically inhibited by
physiologic concentrations of glutathione. (III) The impact
of a pre-existing ATP depletion in the successive step causes
GSH not to be synthesized through glutathione synthetase,
which can also be caused by glycine deficiency. Additionally,
low levels of GSH increase gamma-glutamylcysteine syn-
thase activity.
Under cysteine-limiting conditions, Glu is recycled
into Glu (a futile cycle) via 5-oxoprolinase at the ex-
pense of two ATP molecules without GSH production
and this is the reason for the decrease in GSH synthesis
as well as the depletion of ATP in these cells [14]. This
futile cycle is activated by the depletion of both glutathi-
one and cysteine. The probable cysteine insufficiency
will be developed later.
Fig. 2 The comparative analysis of severity, ventilation (FiO2) and
clinical parameters (PCT, LDH, and lactic acid) with both urinary and
serum glutamic and pyroglutamic acid levels, and the erythrocyte
GPX activity at initial. The cutoff scores were established by the
median (low levels vs high levels)
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On the other hand, a disturbance can be observed in
the levels of the components of the homocysteine cycle,
which is shown in Fig. 4. Basal homocysteine levels have
been found to not be associated with the severity and
mortality of septic patients [15]. In a study by Tsantes et
al. [16], basal homocysteine levels in sepsis patients were
observed to be within normal levels. However, the levels
of vit B12 were higher, as in this study. According to the
homocysteine cycle, the elimination of homocysteine is
geared towards the formation of methionine through the
increase of this vitamin (vit B12) and not towards the
formation of cysteine. In addition, epidemiological evi-
dence indicates that patients with inflammation have sig-
nificantly lower blood levels of pyridoxal 5′-phosphate
PLP (vit B6) than control subjects [17–19]. According to
this study, there is a positive correlation between Glu
and vit B12; that is to say, Glu accumulates when vit
B12 increases, since cysteine is not available for the
gamma-glutamylcysteine synthetase to act to form
gamma-glutamylcysteine, as shown in Fig. 1. A study by
Hirose et al. [20] revealed the minimum value of glutam-
ate and the maximum value of methionine to be signifi-
cant prognostic factors for mortality in patients with
sepsis.
There are correlations between PyroGlu, Glu, and
GPX1 activity and some biochemical, respiratory, and
severity markers. This shows the association between
the parameters of the glutathione pathway and the meta-
bolic alteration in these patients. Excess PyroGlu in a
septic patient without enzymatic deficiency in the
gamma-glutamyl cycle could be associated with the de-
pletion of GSH, and therefore excessive oxidative stress
and its negative consequences. Low GSH and increased
GSSG are expected in a situation of oxidative stress and
increase of redox potential. Nevertheless, the increase of
PyroGlu and decrease of Glu seems more reflecting the
low ATP cellular content leading to a locking of the
gamma-glutamyl cycle from the first step requiring ATP
after PyroGlu synthesis. GSH metabolism is demon-
strated to be significantly altered by malnutrition and
Fig. 3 a–d Spearman’s correlation analysis between pyroglutamic and glutamic acid in serum and urine
Fig. 4 Homocysteine cycle. Cysteine is required for the formation of
glutathione. Cysteine comes from homocysteine. Homocysteine also
intervenes in the formation of methionine, for which it requires folic
acid and vitamin B12
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28-day mortality in ICU patients [21]. In one study [22],
blood GSH concentrations and synthesis rates were
found to have decreased in children with sepsis, while
blood GSH redox ratios (GSSG:GSH) were found to
have increased [23], suggesting increased oxidative
stress. Numerous studies associate low GSH levels with
PyroGlu increase [24–26]. Likewise, high levels of Pyro-
Glu are associated with high oxidative stress [27, 28]. In
a study by Metges et al. [29], it was confirmed that gly-
cine or sulfur amino acid restriction alters PyroGlu kin-
etics and urinary excretion, another reason which
explains how altering the precursors of GSH formation
also alters the gamma-glutamyl cycle.
A significant decrease in the final SOFA score was ob-
served as a consequence of the support measures carried
out in the ICU. However, final PyroGlu increased signifi-
cantly, without being affected by these measures. This
may be a reason why there is no association between
PyroGlu and clinical severity parameters. Therefore, Pyr-
oGlu might be considered as a glutathione depletion
marker, which acts independently of severity scales. We
propose that PyroGlu should be evaluated in critical pa-
tients with septic shock.
The overall redox potential of a cell is primarily deter-
mined by oxidizable/reducible chemical pairs, including
GSH/GSSH, reduced thioredoxin/oxidized thioredoxin,
NAD+/NADH, and NADP+/NADPH, as shown in Fig. 5.
Expending the known reduced species (NADH+, re-
duced glutathione, etc.) to “neutralize” the deleterious
compounds weakens the organism’s capacity to combat
further oxidative stress. GPX1 is one of the most abun-
dant members of the GPX family of enzymes. GPX fam-
ily is present in all cells, primarily located in the
cytosolic and mitochondrial compartments, as well as
the peroxisomal compartment [30] in some cells. It has
been found to be more effective than catalase at remov-
ing intracellular peroxides under many physiological
conditions [31]. In this study, these patients have been
observed to have GPX1 activity that does not contribute
to the elimination of free radicals because it is decreased
with respect to control patients. Although numerous
studies have measured GPX1 activity in patients with
sepsis, the results remain inconclusive [32, 33].
As for Se levels, we found a significant decrease in
plasma in relation to an ICU stay. This decrease has
been repeatedly observed in sepsis patients since 1998
[34]. It is related to the binding of selenoprotein-P to
the endothelium in sepsis, to the protein extravasation
at the early phase of sepsis, and to downregulation of
selenoprotein-P liver synthesis [33]. We found a signifi-
cant decrease in erythrocytes in relation to an ICU stay.
Erythrocyte Se content does not interfere with sepsis.
However, erythrocyte Se content is an accurate marker
of Se status prior to septic shock [35–37] and is a good
marker of longer-term Se status [38]. Certain parts of
Granada’s population with a possible low selenium in-
take [38], such as patients with HIV or cancer, could be
concerned by such deficiency. Previous Se deficiency is
expected to reduce resistance to oxidative stress. The
variation in initial and final erythrocyte Se concentration
might be related to transfusion, hemolysis, or the death
of some patients. It has long been known that the lethal
Keshan disease is related to major Se deficiency. This Se
deficiency induced mortality from myocarditis caused by
coxsackievirus infection [39]. Such disease has been pre-
vented by Se food enrichment in the region of Keshan,
China. We could not associate of Se with the other pa-
rameters studied, likely due to the size of our sample.
Currently, it is admitted that a moderate increase of sel-
enium administration compared to the daily requirement
(with a maximum of about 300 μg/day) is largely suffi-
cient in septic patients, even under dialysis or suffering
an extended burn. This dose is lower than the US Upper
Limit. For the record, the body selenium content is
about 10 to 20 mg, and the plasma compartment con-
tains only a small fraction of body selenium content (less
than 2%). Se is included in GPX at the active site of the
enzyme under the form of the amino acid selenocys-
teine, which is required for its activity; therefore, supple-
mentation is of vital importance in patients who do not
have sufficient levels of Se. A prospective observational
study [40] showed that erythrocyte Se concentration pre-
dicts mortality in patients with septic shock. High dose
Se supplementation has not improved the clinical out-
come of septic shock patients [41], although these stud-
ies are controversial [42].
Fig. 5 Oxide reduced cycle. Glutathione peroxidase-1 (GPX1) is an intracellular antioxidant enzyme that enzymatically reduces hydrogen peroxide
to water to limit its harmful effects. GPX glutathione peroxidase, GRd glutathione reductase
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Thiol antioxidants such as N-acetyl-L-cysteine (NAC)
have been shown to be beneficial against inflammation.
Thus, along with its properties as an antioxidant, NAC will
also increase GSH, possibly preserving or enhancing GPX1
function [43]. Gamma-glutamyl transpeptidase (GGT) plays
key roles in GSH homeostasis by breaking down extracellu-
lar GSH and providing cysteine, the rate-limiting substrate,
for the intracellular de novo synthesis of GSH. The pres-
ence of ROS and oxidative stress in sepsis, especially in sep-
tic shock, has led several studies to evaluate the role of
NAC as adjuvant therapy [7, 44–50]. It is also important to
suspend medications such as paracetamol or flucloxacillin
in patients who manifest pyroglutamic acidemia so as not
to further contribute to its increase [51, 52]. The key to the
controversy surrounding the administration of NAC in
these cases may be that these patients have depleted ATP
and the last reaction of the detailed cycle (glutathione syn-
thetase) is limited and GSH is not synthesized.
Oxidative stress determination is limited in daily clin-
ical practice, primarily due to the difficulty in measuring
the different aspects of oxidative stress, which entails
several tests: oxidized glutathione, reduced glutathione,
glutathione peroxidase, and glutathione reductase (GRd).
This study proposes using the parameter of PyroGlu as a
predictor of oxidative stress due to GSH depletion.
There is a significant positive correlation between Pyro-
Glu in serum and in urine (Fig. 3b); therefore, we could
propose that it can be measured in urine since the sam-
ple is easier to obtain. Although PyroGlu is not routinely
available in clinical laboratories, this study presents data
that supports its usefulness, though more work is
needed before being used in clinical practice.
Conclusions
Patients with septic shock manifest pyroglutamic acidosis
that correlates with low levels of Glu (except urine Glu/
Crea) which can be measured in both serum and urine,
and low GPX1/Hb activity. Glu is related to severity pa-
rameters and vit B12, although this relationship is not ob-
served in the case of PyroGlu nor GPX1. The major
contribution of this study is the strengthening of evidence
to support the control of patients with pyroglutamic acid-
osis, in addition to proposing PyroGlu as a way to meas-
ure oxidative stress. These results could offer new data
that can lead to future studies on recognizing the increase
in pyroglutamic acidosis as an indicator of GSH depletion.
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